F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: A patent review

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 9, 2015, Pages 991-1002

  Yang, Hong ^a   Ma, Tonghui ^b  

^a LIAONING NORMAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

cystic fibrosis; cystic fibrosis transmembrane regulator; cystic fibrosis transmembrane regulator corrector; cystic fibrosis transmembrane regulator modulator; cystic fibrosis transmembrane regulator potentiator; ivacaftor; lumacaftor

Indexed keywords

AMIDE; COUMARIN DERIVATIVE; CYCLOPROPANE DERIVATIVE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HETEROCYCLIC COMPOUND; ION TRANSPORT AFFECTING AGENT; IVACAFTOR; LUMACAFTOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

CHANNEL GATING; CYSTIC FIBROSIS; DRUG SCREENING; HUMAN; NONHUMAN; PATENT; PROTEIN STABILITY; REVIEW; DRUG DESIGN; GENETICS; MUTATION;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; HUMANS; MUTATION; PATENTS AS TOPIC; QUINOLONES;

EID: 84940175288     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1045878     Document Type: Review

References (109)

1. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: Genetic analysis. Science 1989; 245: 1073-80
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989; 245: 1066-73
3. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 1989; 245: 1059-65
4. American Lung Association. In: State of Lung Disease in Diverse Communities 2010. 2010; 41-4. Available from: http://www.lung.org/assets/documents/publications/lung-disease-data/solddc-2010.pdf [Last accessed 1 January 2015]
5. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008; 7: 450-3
6. Trezise AE, Buchwald M. In vivo cellspecific expression of the cystic fibrosis transmembrane conductance regulator. Nature 1991; 353: 434-7
7. Kunzelmann K. The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 1999; 137: 1-70
8. Riordan JR. CFTR function and prospects for therapy. Ann Rev Biochem 2008; 77: 701-26
9. Crawford I, Maloney PC, Zeitlin PL, et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci U S A 1991; 88: 9262-6
10. Frizzell RA, Hanrahan JW. Physiology of epithelial chloride and fluid secretion. Cold Spring Harb Perspect Med 2012; 2: a009563
11. Chambers LA, Rollins BM, Tarran R. Liquid movement across the surface epithelium of large airways. Respir Physiol Neurobiol 2007; 159: 256-70
12. Thiagarajah JR, Verkman AS. CFTR pharmacology and its role in intestinal fluid secretion. Curr Opin Pharmacol 2003; 3: 594-9
13. Venkatasubramanian J, Ao M, Rao MC. Ion transport in the small intestine. Curr Opin Gastroenterol 2010; 26: 123-8
14. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-4.
15. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891-904
16. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011; 139: 1480-90.
17. Gazvani R, Lewis-Jones I. Cystic fibrosis screening in assisted reproduction. Curr Opin Obstet Gynecol 2006; 18(3): 268-72
18. Denning GM, Ostedgaard LS, Welsh MJ. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol 1992; 118: 551-9
19. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991; 354: 526-8
20. Kartner N, Augustinas O, Jensen TJ, et al. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1992; 1: 321-7
21. Dalemans W, Hinnrasky J, Slos P, et al. Immunocytochemical analysis reveals differences between the subcellular localization of normal and delta Phe508 recombinant cystic fibrosis transmembrane conductance regulator. Exp Cell Res 1992; 201: 235-40
22. Ng MY, Flight W, Smith E. Pulmonary complications of cystic fibrosis. Clin Radiol 2014; 69: e153-62
23. Dhooghe B, Noe?l S, Huaux F, Leal T. Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem 2014; 47: 539-46
24. McCaughey G, Gilpin D, Elborn J, Tunney MM. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Rev Respir Med 2013; 7: 385-96
25. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009; 54: 595-605
26. Jain M, Goss CH. Update in cystic fibrosis 2013. Am J Respir Crit Care Med 2014; 189: 1181-6
27. Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir Med 2013; 1: 148-57
28. Chmiel JF, Konstan MW, Elborn JS. Antibiotic and anti-inflammatory therapies for cystic fibrosis. Cold Spring Harb Perspect Med 2013; 3: a009779
29. Wilson R, Sethi S, Anzueto A, Miravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect 2013; 67: 497-515
30. Peters S. Cystic fibrosis: a review of pathophysiology and current treatment recommendations. S D Med 2014; 67: 148-51, 153
31. Ratjen F, Döring G. Cystic fibrosis. Lancet 2003; 361: 681-9
32. Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 2007; 13: 541-6
33. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006; 12: 428-32
34. Atkinson TJ. Cystic fibrosis, vectormediated gene therapy, and relevance of toll-like receptors: a review of problems, progress, and possibilities. Curr Gene Ther 2008; 8: 201-7
35. Armstrong DK, Cunningham S, Davies JC, Alton EW. Gene therapy in cystic fibrosis. Arch Dis Child 2014; 99: 465-8
36. Griesenbach U, Alton EW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 2013; 22: R52-8.
37. Prickett M, Jain M. Gene therapy in cystic fibrosis. Transl Res 2013; 161: 255-64
38. Denning G, Anderson M, Amara J, et al. Processing of mutant cytsic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-3.
39. Sato S, Ward CL, Krouse ME, et al. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996; 271: 635-8.
40. Brown CR, Hong-Brown LQ, Biwersi J, et al. Chemical chaperones correct the mutant phenotype of the DF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996; 1: 117-25
41. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in F508delhomozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-90
42. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100: 2457-65
43. Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 2013; 3(7): pii: a009761
44. Pettit RS. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother 2012; 46: 1065-75
45. Deeks ED. Ivacaftor: a review of its use in patients with cystic fibrosis. Drugs 2013; 73: 1595-604
46. Merk D, Schubert-Zsilavecz M. Repairing mutated proteins-development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator. Expert Opin Drug Discov 2013; 8: 691-708
47. Pasyk S, Molinski S, Yu W, et al. Identification and validation of hits from high throughput screens for CFTR modulators. Curr Pharm Des 2012; 18: 628-41
48. Becq F. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. Drugs 2010; 70: 241-59
49. Pettit RS, Fellner C. CFTR. Modulators for the Treatment of Cystic Fibrosis. P T 2014; 39: 500-11.
50. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009; 8: 153-71
51. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108: 18843-8.
52. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797-807
53. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003; 278: 35079-85
54. Pettit RS, Fellner C. CFTR. Modulators for the Treatment of Cystic Fibrosis. P T 2014; 39: 500-11
55. Vertex Pharmaceuticals. U.S. Food and Drug Administration Approves KALYDECO(ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis. 2014. Available from: http://investors.vrtx.com/releasedetail. cfm?ReleaseID=827435 [Last accessed on 28 January 2015]
56. Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 2013; 24: 3016-24
57. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del- CFTR mutation. Thorax 2012; 67: 12-18
58. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014; 2: 527-38
59. A study of lumacaftor in combination with ivacaftor in cystic fibrosis subjects aged 12 years and older who are homozygous for the F508del-CFTR mutation (TRANSPORT). Available from: https://clinicaltrials.gov/ct2/show/record/NCT01807949 [Last accessed on 16 March 2015]
60. A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC). Available from: https://clinicaltrials.gov/ct2/show/NCT01807923 [Last accessed on 16 March 2015]
61. FirstWord Pharma. Vertex's Kalydeco, lumacaftor combination meets main goals of cystic fibrosis Phase III trials. 2014. Available from: http://www. firstwordpharma.com/node/1219447#axzz3Q5NRiPtZ [Last accessed on 28 January 2015]
62. Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of DF508 CFTR in cystic fibrosis. Sci Transl Med 2014; 6(246): 246ra96
63. Seeking Alpha. Vertex Pharma off on trial data for VX-661. 2015. Available from: http://seekingalpha.com/news/2385656-vertexpharma-off-on-trial-data-for-vxminus-661?auth-param=11sf95: 1ah0949: c0eace6e7379e65e5b921 6347ff7e872&uprof=. 61 [Last accessed on 23 March 2015]
64. Norman P. Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386 and. WO2013038390. Expert Opin Ther Pat 2014.24(7): 829-37.
65. Cystic Fibrosis Foundation Therapeutic INC. Pyrimidine compounds and methods of making and using same. WO068863; 2010
66. Cystic Fibrosis Foundation Therapeutic INC. Pyrimine compounds and methods of making and using same. WO151747; 2010
67. Cystic Fibrosis Foundation Therapeutic INC. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders. WO008931; 2011
68. Verkman AS, Pedemont N, Galietta LJV. Compounds having activity in correcting mutant-CFTR processing and uses thereof. WO101740; 2006
69. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-71
70. Ye L, Hu B, El-Badri F, et al. DF508-CFTR correctors: Synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles. Bioorg Med Chem Lett 2014; 24: 5840-4
71. Donald MB, Rodriguez KX, Shay H, et al. Click-based synthesis of triazolobithiazole DF508-CFTR correctors for cystic fibrosis. Bioorg Med Chem 2012; 20: 5247-53
72. Ye L, Knapp JM, Sangwung P, et al. Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles. J Med Chem 2013; 53: 3772-81
73. Yu GJ, Yoo CL, Yang B, et al. Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J Med Chem 2008; 51: 6044-54
74. Loo TW, Bartlett MC, Clarke DM. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm 2005; 2: 407-13
75. Loo TW, Bartlett MC, Wang Y, Clarke DM. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTRprocessing mutants. Biochem J 2006; 395: 537-42
76. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-30
77. Suen YF, Robins L, Yang B, et al. Sulfamoyl-4-oxoquinoline-3- carboxamides: novel potentiators of defective DeltaF508-cystic fibrosis transmembrane conductance regulator chloride channel gating. Bioorg Med Chem Lett 2006; 16: 537-40
78. Phuan PW, Yang B, Knapp JM, et al. Cyanoquinolines with independent corrector and potentiator activities restore DPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol Pharmacol 2011; 80: 683-93
79. Knapp JM, Wood AB, Phuan PW, et al. Structure-activity relationships of cyanoquinolines with correctorpotentiator activity in DF508 cystic fibrosis transmembrane conductance regulator protein. J Med Chem 2012; 55: 1242-51
80. Verkman AS, Phuan P, Kurth MJ, Knapp J. Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof. WO166654; 2012
81. DiscoveryBiomed INC. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders. WO152213; 2014
82. Cabrini G, Casavola V, Gambari R. Trimethylangelicin as cftr corrector in bronchial epithelial cells. WO171954; 2012
83. Favia M, Mancini MT, Bezzerri V, et al. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. Am J Physiol Lung Cell Mol Physiol 2014; 307: L48-61
84. Xu LN, NaWL, Liu X, et al. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating. Clin Exp Pharmacol Physiol 2008; 35: 878-83
85. Yang H, Xu LN, Sui YJ, et al. Stimulation of Airway and Intestinal Mucosal Secretion by Natural Coumarin CFTR Activators. Front Pharmacol 2011; 2: 52
86. Wu L, Wang X, Xu W, et al. The structure and pharmacological functions of coumarins and their derivatives. Curr Med Chem 2009; 16: 4236-60
87. DiscoveryBiomed INC. Small molecule bicyclic and tricyclic cftr correctors. WO081821; 2014
88. DiscoveryBiomed INC. Small molecule cftr correctors. WO081820; 2014
89. Prehm P. Compounds having activity in correcting mutant CFTR cellular processing. WO066912; 2010
90. Vertex Pharmaceuticals. Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis. 2015. Available from: http://investors. vrtx.com/releasedetail.cfm? ReleaseID=890626 [Last accessed on 28 January 2015]
91. Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish DF508-CFTR functional expression. Sci Transl Med 2014; 6(246): 246ra97
92. Okiyoneda T, Veit G, Dekkers JF, et al. Mechanism-based corrector combination restores DF508-CFTR folding and function. Nat Chem Biol 2013; 444-54
93. Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore DF508 CFTR folding and function. Cell 2012; 148: 150-63.
94. Farinha CM, King-Underwood J, Sousa M, et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol 2013; 20: 943-55
95. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DF508 conformational defect. Trends Mol Med 2012; 18: 81-91
96. Jiang M, Yang J, Zhang C, et al. Clinical studies with traditional Chinese medicine in the past decade and future research and development. Planta Med 2010; 76: 2048-64
97. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy-from TCM theory to mechanistic insights. Planta Med 2010; 76: 1118-31
98. Zhang Y, Yu B, Sui Y, et al. Identification of resveratrol oligomers as inhibitors of cystic fibrosis transmembrane conductance regulator by high-throughput screening of natural products from chinese medicinal plants. PLoS One 2014; 9: e94302
99. Luan J, Zhang Y, Yang S, et al. Oridonin: A small molecule inhibitor of cystic fibrosis transmembrane conductance regulator (CFTR) isolated from traditional Chinese medicine. Fitoterapia 2014; 100C: 88-94
100. Chen L, Yu B, Zhang Y, et al. Bioactivity-guided Fractionation of an Antidiarrheal Chinese Herb Rhodiola kirilowii (Regel) Maxim Reveals (-)- epicatechin-3-gallate and (-)- epigallocatechin-3-gallate as Inhibitors of Cystic Fibrosis Transmembrane Conductance Regulator. PLoS ONE 2015; 10(3): e0119122
101. Kopeikin Z, Yuksek Z, Yang HY, Bompadre SG. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del- CFTR channels. J Cyst Fibros 2014; 13: 508-14
102. Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 2013; 3: a009761
103. Vertex Pharmaceutical Incorporated. Modulators of ATP-binding cassette transporters. WO075435; 2005.
104. Vertex Pharmaceutical Incorporated. Modulators of cystic fibrosis transmembrane conductance regulator. WO021982; 2007
105. Vertex Pharmaceutical Incorporated. Azaindole derivatives as CFTR modulators. WO127399; 2008
106. Vertex Pharmaceutical Incorporated. Heteroaryl derivatives as CFTR modulators. WO108657; 2009
107. Vertex Pharmaceutical Incorporated Pyridyl derivatives as CFTR modulators. WO123896; 2009
108. Vertex Pharmaceutical Incorporated. Formulations of 3-(6-(1-(2.2- difluorobenzo[d][1, 3]dioxol-5-yl) cyclopropanecarboxamido)-3- methylpyridin-2-yl)benzoic acid. WO112804; 2013
109. Vertex Pharmaceutical Incorporated. Pharmaceutical compositions of (r)-1-(2, 2- diflurorbenzo[d][1, 3]dioxol-5-yl)-n-(1- (2, 3-dihydroxypropyl)-6-fluoro-2-(1- hydroxy-2-methylpropan-2-yl)-1h-indol-5- yl) cyclopropanecarboxamide and administration thereof. WO014841; 2014